DB
NMRA icon

Dmitry Balyasny’s Neumora Therapeutics NMRA Stock Holding History

Dmitry Balyasny’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,642
Closed -$112K – 3349
2026
Q1 		$112K Buy
+57,642
New +$149K ﹤0.01% 2749
2024
Q3 		– Sell
-380,160
Closed -$3.74M – 3021
2024
Q2 		$3.74M Sell
380,160
-308,009
-45% -$3.19M 0.01% 1303
2024
Q1 		$9.46M Buy
+688,169
New +$11.1M 0.02% 954

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dmitry Balyasny's NMRA Position: Q2 2026 in Review

Dmitry Balyasny sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 57,642 shares — an estimated $112K sold.

Dmitry Balyasny first reported a position in NMRA in Q1 2024 and held it in 3 quarters. The position peaked at $9.46M in Q1 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Dmitry Balyasny reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 57,642 Neumora Therapeutics shares in Q2 2026, an estimated $112K.
  • Dmitry Balyasny first reported a position in Neumora Therapeutics in Q1 2024 and held it in 3 quarters.
  • Dmitry Balyasny's Neumora Therapeutics position peaked at $9.46M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.